Chemed Corporation $CHE Shares Sold by William Allan Corp

William Allan Corp cut its position in Chemed Corporation (NYSE:CHE) by 1.3% in the second quarter, Holdings Channel reports. The firm owned 8,246 shares of the company’s stock after selling 105 shares during the period. Chemed accounts for approximately 2.3% of William Allan Corp’s holdings, making the stock its 18th biggest position. William Allan Corp’s holdings in Chemed were worth $4,015,000 at the end of the most recent quarter.

A number of other large investors have also recently made changes to their positions in CHE. HM Payson & Co. acquired a new stake in shares of Chemed in the 1st quarter valued at about $30,000. SVB Wealth LLC acquired a new stake in shares of Chemed in the 1st quarter valued at about $30,000. WPG Advisers LLC acquired a new stake in shares of Chemed in the 1st quarter valued at about $32,000. Geneos Wealth Management Inc. boosted its position in shares of Chemed by 330.4% in the 1st quarter. Geneos Wealth Management Inc. now owns 99 shares of the company’s stock valued at $61,000 after purchasing an additional 76 shares during the period. Finally, Zions Bancorporation National Association UT acquired a new stake in shares of Chemed in the 1st quarter valued at about $68,000. 95.85% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other news, Director Patrick P. Grace sold 150 shares of the stock in a transaction that occurred on Tuesday, September 9th. The stock was sold at an average price of $463.39, for a total transaction of $69,508.50. Following the completion of the transaction, the director directly owned 3,397 shares of the company’s stock, valued at approximately $1,574,135.83. This represents a 4.23% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, Director George J. Walsh III acquired 200 shares of the company’s stock in a transaction that occurred on Monday, August 4th. The stock was purchased at an average cost of $417.10 per share, with a total value of $83,420.00. Following the completion of the purchase, the director directly owned 3,523 shares in the company, valued at $1,469,443.30. This represents a 6.02% increase in their ownership of the stock. The disclosure for this purchase can be found here. In the last quarter, insiders sold 13,162 shares of company stock valued at $5,677,511. Corporate insiders own 3.29% of the company’s stock.

Analyst Ratings Changes

A number of analysts have weighed in on CHE shares. Royal Bank Of Canada decreased their price objective on Chemed from $640.00 to $589.00 and set an “outperform” rating for the company in a research report on Thursday, July 31st. Wall Street Zen cut Chemed from a “buy” rating to a “hold” rating in a research note on Saturday, July 5th. Oppenheimer decreased their price target on Chemed from $650.00 to $580.00 and set an “outperform” rating for the company in a report on Thursday, July 31st. Jefferies Financial Group raised Chemed from a “hold” rating to a “buy” rating and increased their price target for the stock from $490.00 to $550.00 in a report on Tuesday, September 2nd. Finally, Bank of America decreased their price target on Chemed from $610.00 to $595.00 and set a “buy” rating for the company in a report on Wednesday, September 10th. Four analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $578.50.

Chemed Trading Up 0.3%

Shares of CHE stock opened at $437.92 on Tuesday. The company has a market cap of $6.38 billion, a price-to-earnings ratio of 22.52, a price-to-earnings-growth ratio of 2.52 and a beta of 0.43. The stock has a 50 day simple moving average of $448.37 and a 200-day simple moving average of $496.86. Chemed Corporation has a 12-month low of $408.42 and a 12-month high of $623.60.

Chemed (NYSE:CHE) last issued its earnings results on Tuesday, July 29th. The company reported $4.27 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $6.02 by ($1.75). The business had revenue of $618.80 million for the quarter, compared to analysts’ expectations of $650.60 million. Chemed had a return on equity of 25.83% and a net margin of 11.56%.The business’s quarterly revenue was up 3.8% on a year-over-year basis. During the same period last year, the company posted $5.47 earnings per share. On average, equities analysts forecast that Chemed Corporation will post 21.43 earnings per share for the current fiscal year.

Chemed Increases Dividend

The firm also recently announced a quarterly dividend, which was paid on Friday, August 29th. Stockholders of record on Monday, August 11th were paid a dividend of $0.60 per share. This is a positive change from Chemed’s previous quarterly dividend of $0.50. The ex-dividend date of this dividend was Monday, August 11th. This represents a $2.40 dividend on an annualized basis and a dividend yield of 0.5%. Chemed’s dividend payout ratio (DPR) is currently 12.34%.

About Chemed

Chemed Corporation provides hospice and palliative care services to patients through a network of physicians, registered nurses, home health aides, social workers, clergy, and volunteers primarily in the United States. The company operates in VITAS and Roto-Rooter segments. It offers plumbing, drain cleaning, excavation, water restoration, and other related services to residential and commercial customers through company-owned branches, independent contractors, and franchisees.